Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shuren: New Clinical Trial Guidelines In The Works

This article was originally published in The Gray Sheet

Executive Summary

FDA device center director Jeffrey Shuren says new guidance documents coming down the pike will clarify issues related to clinical trial design and approval.

You may also be interested in...



Jumpstarting U.S. Device Trials? FDA Makes Effort In New Draft Guidelines

New FDA guidances aim to strike a balance by allowing firms to begin trials earlier through adaptive study designs, while ensuring that patients are adequately protected.

FDA Dx Office Plans Pilot 510(k) ‘Triage’ Program For Early 2012

FDA’s diagnostics office will begin a pilot program in early 2012 to triage its review of 510(k) submissions based on product risk and application quality.

FDA Dx Office Plans Pilot 510(k) ‘Triage’ Program For Early 2012

FDA’s diagnostics office will begin a pilot program in early 2012 to triage its review of 510(k) submissions based on product risk and application quality.

Related Content

UsernamePublicRestriction

Register

MT030251

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel